These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33742143)

  • 1. Does a high Mandard score really define a poor response to chemotherapy in oesophageal adenocarcinoma?
    Knight WRC; Baker CR; Griffin N; Wulaningsih W; Kelly M; Davies AR; Gossage JA;
    Br J Cancer; 2021 May; 124(10):1653-1660. PubMed ID: 33742143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    Noble F; Nolan L; Bateman AC; Byrne JP; Kelly JJ; Bailey IS; Sharland DM; Rees CN; Iveson TJ; Underwood TJ; Bateman AR
    World J Gastroenterol; 2013 Dec; 19(48):9282-93. PubMed ID: 24409055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
    Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
    J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus.
    Knight WRC; Yip C; Wulaningsih W; Jacques A; Griffin N; Zylstra J; Van Hemelrijck M; Maisey N; Gaya A; Baker CR; Kelly M; Gossage JA; Lagergren J; Landau D; Goh V; Davies AR; ; Ngan S; Qureshi A; Deere H; Green M; Chang F; Mahadeva U; Gill-Barman B; George S; Dunn J; Zeki S; Meenan J; Hynes O; Tham G; Iezzi C
    BJS Open; 2019 Dec; 3(6):767-776. PubMed ID: 31832583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
    Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
    Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
    Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    Zhu Y; Sun Y; Hu S; Jiang Y; Yue J; Xue X; Yang L; Xue L
    BMC Gastroenterol; 2017 Mar; 17(1):41. PubMed ID: 28292272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
    Karamitopoulou E; Thies S; Zlobec I; Ott K; Feith M; Slotta-Huspenina J; Lordick F; Becker K; Langer R
    Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
    Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
    Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin.
    Bott RK; Beckmann K; Zylstra J; Wilkinson MJ; Knight WRC; Baker CR; Kelly M; Maisey N; Qureshi A; Sevitt T; Van Hemelrijck M; Smyth EC; Allum WH; Lagergren J; Gossage JA; Cunningham D; Davies AR;
    Br J Surg; 2020 Dec; 107(13):1801-1810. PubMed ID: 32990343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
    Kersting S; Konopke R; Dittert D; Distler M; Rückert F; Gastmeier J; Baretton GB; Saeger HD
    J Gastroenterol Hepatol; 2009 May; 24(5):886-95. PubMed ID: 19655439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemoradiation for patients with advanced oesophageal cancer - which response grading system best impacts prognostic discrimination?
    Puetz K; Bollschweiler E; Semrau R; Mönig SP; Hölscher AH; Drebber U
    Histopathology; 2019 Apr; 74(5):731-743. PubMed ID: 30636069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
    Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma.
    Aboul-Enein MS; Knight W; Wulaningsih W; Foley DM; Dellaportas D; Zylstra J; Baker CR; Kelly M; Smyth E; Lagergren J; Maisey N; Allum WH; Gossage JA; Cunningham D; Davies AR;
    J Surg Oncol; 2021 Dec; 124(8):1296-1305. PubMed ID: 34403501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil to lymphocyte ratio as a predictor of response to neoadjuvant chemotherapy and survival in oesophageal adenocarcinoma.
    Powell AGMT; Chin C; Coxon AH; Chalishazar A; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Jun; 4(3):416-423. PubMed ID: 32232963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
    Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
    Br J Surg; 2017 Mar; 104(4):408-417. PubMed ID: 28093719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Spierings LE; Lagarde SM; van Oijen MG; Gisbertz SS; Wilmink JW; Hulshof MC; Meijer SL; Anderegg MC; van Berge Henegouwen MI; van Laarhoven HW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S766-71. PubMed ID: 26350367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor regression grades: potential outcome predictor of locally advanced rectal adenocarcinoma after preoperative radiotherapy.
    Peng YF; Yu WD; Pan HD; Wang L; Li M; Yao YF; Zhao J; Gu J
    World J Gastroenterol; 2015 Feb; 21(6):1851-6. PubMed ID: 25684951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.